ladiratuzumab vedotin
mAbexperimentalADC
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2013 (NCT01969643)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Melanoma · Phase 2
- Prostatic Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Zinc transporter ZIP6BINDING AGENT
Zinc transporter ZIP6 binding agent
- Zinc transporter ZIP6INHIBITOR
SLC39A6 inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
Beta tubulin vinca binding domain
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
- Zinc transporter ZIP6Immunity, passive
SLC39A6 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Monomethylauristatin E
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298101 ↗
Also known as
- sgn-liv1a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04032704 | Phase 2 | Aug 31, 2019 | Seattle Genetics |
| NCT03424005 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2018 | Roche, Seattle Genetics |
| NCT03310957 | Phase 1/Phase 2 (Phase 2) | Feb 27, 2018 | Merck, Seattle Genetics |
| NCT01969643 | Phase 1 | Sep 1, 2013 | Seattle Genetics |
| NCT06362590 | N/A | — | Seattle Genetics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seattle Genetics | For profit | 5 | 4 | 3 | 2013 |
| Merck | For profit | 1 | 0 | 1 | 2018 |
| Roche | For profit | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1